Person:
SAPAN, NİHAT

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

SAPAN

First Name

NİHAT

Name

Search Results

Now showing 1 - 10 of 35
  • Publication
    The use of cyclosporine a in the treatment of toxic epidermal necrolysis; case report and review of literature
    (Galenos Yayincilik, 2014-08-01) Canıtez, Yakup; CANITEZ, YAKUP; Çekiç, Şükrü; ÇEKİÇ, ŞÜKRÜ; Sapan, Nihat; SAPAN, NİHAT; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0002-9574-1842; L-1933-2017
    Toxic epidermal necrolysis (TEN) is a serious and life-threatening acute mucocutaneous disease that is often triggered by drugs, can affect skin, eyes, mucous membranes and multiple organs.While an eleven-year-old female patient with epilepsy had been using valproic acid for three years, lamotrigine was added to the treatment one month ago. The patient was admitted complaints such as fever, malaise, sores in the mouth, eye redness, watering of eyes, rashes and many bullous lesions in the skin that had started just 2 days earlier. On the physical examination, whose overall situation was bad, that were common maculopapular rash, purpuric macules on the whole body, atypical target-like skin lesions, and many bullae that affected more than 30% of the body in different stages and whose largest one was 6-10 cm in diameter were detected. There were ulcerated lesions in the oral mucosa and keratitis, blepharitis and conjunctival hyperemia in both eyes. The patient was diagnosed with TEN through the existing findings. The lamotrigine treatment was discontinued; the supportive treatment, methylprednisolone, intravenous immunoglobulin, necessary care for skin and eye lesions and the necessary topical treatment were applied. As no improvement was observed in clinical picture and skin lesions in the follow-up period, cyclosporine A was added to the treatment. Significant improvement was observed in the clinical picture and skin lesions of the patient who responded well to the treatment of cyclosporine A.The basis of the treatment of TEN is composed of discontinuation of the suspicious drug and the supportive therapy. The immunosuppressive agents such as systemic corticosteroids and IVIG therapy may be used in the treatment of TEN. Cyclosporine can positively contribute to the treatment in cases who are resistant to treatment and with a severe TEN condition. There is a need for in-depth studies to investigate the place and impact of cyclosporine in the treatment of TEN.
  • Publication
    The efficacy of inhaled hypertonic saline in children with cystic fibrosis who receive daily DNase
    (European Respiratory Soc Journals Ltd, 2022-09-04) Gençoğlu, M. Y.; Tuğcu, G. D.; Soydaş, S. S. Akyan; Cinel, G.; Emiralioglu, N.; Yalçın, E.; Kiper, N.; Sen, V; Altintas, D. Ufuk; Cokugras, H.; Kilinc, A. Ayzit; Yazan, H.; Unal, G.; Yilmaz, A., I; Caglar, H. T.; Damadoglu, E.; Irmak, I.; Demir, E.; Ozturk, G.; Bingol, A.; Basaran, E.; Sapan, N.; Aslan, A. T.; Asfuroglu, P.; Harmanci, K.; Kose, M.; Hangul, M.; Ozdemir, A.; Ozcan, G.; Gayretli, Z. G.; Keskin, O.; Yuksel, H.; Ozdogan, S.; Topal, E.; Caltepe, G.; Can, D.; Ekren, P. Korkmaz; Kilic, M.; Eyuboglu, T. Sismanlar; Pekcan, S.; Cobanoglu, N.; Cakir, E.; Ozcelik, U.; Dogru, D.; SAPAN, NİHAT; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; Çocuk Alerji Bilim Dalı; FUI-8766-2022
  • Publication
    Evaluation of the cases with non-cystic fibrosis bronchiectasis
    (Galenos Yayıncılık, 2018-01-01) Korkmaz, Serpil; Canıtez, Yakup; Çekiç, Şükrü; Efe, Hülya Poyraz; Ocakoğlu, Gökhan; Sapan, Nihat; Korkmaz, Serpil; CANITEZ, YAKUP; ÇEKİÇ, ŞÜKRÜ; Efe, Hülya Poyraz; OCAKOĞLU, GÖKHAN; SAPAN, NİHAT; Tıp Fakültesi; Çocuk Alerji Ana Bilim Dalı; 0000-0002-9574-1842; 0000-0002-1114-6051; HLG-6346-2023; L-1933-2017; CJQ-2060-2022; CPN-6371-2022; FFE-8839-2022; FUI-8766-2022
    INTRODUCTION: Bronchiectasis is a chronic inflammatory disease characterized by a permanent dilation of the bronchial wall. We aimed to evaluate pediatric cases diagnosed with non-cystic fibrosis bronchiectasis.METHODS: A total of 98 cases who were diagnosed with non-cystic fibrosis bronchiectasis and were being followed-up between January 2010 and January 2015 at our clinic were included. Clinical, laboratory and radiological evaluations were recorded from patients electronic files.RESULTS: Female to male ratio of the cases was 1.3 (56/42). The median age of the cases was 12.2 years (1-18), the median age of diagnosis was 6 years (1-17 years), and the median duration of follow-up was 38 months (3-140 months).The most common symptom of the cases was cough (n: 91, 93%) followed by sputum expectoration (n: 56, 57%). In the pulmonary function tests performed during the initial phase of diagnosis; restrictive pattern was seen in 29.1% (n = 21) of patients and obstructive pattern was seen in 23.2% (n = 17). Furthermore, in last control visit, restrictive pattern was seen in 17.3% (n=9) of them and obstructive pattern was seen in 44.2% (n = 23). The most frequent etiological cause was infectious diseases (n: 41, 42%). Bronchiectasis was seen most commonly in the left lower lobe of the lung (n: 52, 53%), followed by the right lower lobe (n=32, 33.7%).DISCUSSION and CONCLUSION: Bronchiectasis is still a major health problem in developing countries and causes irreversible damage to the lung when untreated. Postinfectious lung diseases are one of the most important causes of bronchiectasis in children. Early diagnosis improves treatment success.
  • Publication
    Omalizumab treatment in childhood chronic urticaria
    (Wiley, 2018-08-01) Çekiç, Şükrü; Karali, Yasin; Canıtez, Yakup; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; KARALI, YASİN; CANITEZ, YAKUP; SAPAN, NİHAT; Tıp Fakültesi; Pediatri ve Alerji Bölümü; 0000-0002-9574-1842; L-1933-2017; FFS-1974-2022; CJQ-2060-2022; FUI-8766-2022
  • Publication
    A comprehensive assessment of long-term complications in patients with stevens-johnson syndrome and toxic epidermal necrolysis
    (Karger, 2023-07-26) Çekiç, Sükrü; Canıtez, Yakup; Yüksel, Hale; Gündüz, Gamze Ucan; Karalı, Zühal; Yalçınbayır, Özgür; Vural, Pınar; Sapan, Nihat; ÇEKİÇ, ŞÜKRÜ; CANITEZ, YAKUP; Yüksel, Hale; UÇAN GÜNDÜZ, GAMZE; KARALI, ZUHAL; VURAL, AYŞE PINAR; YALÇINBAYIR, ÖZGÜR; SAPAN, NİHAT; Tıp Fakültesi; Çocuk Alerjisi Ana Bilim Dalı; 0000-0002-9574-1842; 0009-0002-4004-449X; 0000-0002-5458-1686; 0000-0002-7311-5277; 0000-0001-8929-679X; L-1933-2017; AAH-1789-2021; IZZ-9492-2023; AAH-6661-2021; CZC-9168-2022; IYJ-9408-2023; GIK-1690-2022; FUI-8766-2022
    Introduction: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome are rare severe hypersensitivity reactions that lead to epithelial sloughing. Studies investigating the chronic multisystem effects of these syndromes and assessing patients in terms of quality of life (QOL), depression, and anxiety in the pediatric population are limited. In this study, we aimed to investigate the long-term effects of these diseases from a multisystem perspective. Method: Sixteen pediatric patients diagnosed with SJS, TEN, and SJS/TEN overlap syndrome were evaluated between September 2020 and March 2021. Physical and eye examinations were performed. To evaluate QOL and psychological status, Children's Dermatology Life Quality Index (CDLQI), Screen for Child Anxiety-Related Emotional Disorders (SCARED), and Children's Depression Inventory (CDI) were conducted. The patients' general characteristics, symptoms, and examination findings at their first admission were retrospectively obtained from the hospital's electronic records. Results: Nineteen percent of the patients were female (n = 3). There were 7 patients (44%) with the diagnosis of SJS, 5 patients (31%) with TEN, and 4 patients (25%) with SJS/TEN overlap. The median follow-up time of the subjects was 6.5 years. The most common sequelae in the chronic period were skin changes (n = 13, 81%). Hyperpigmentation was the most common skin change (n = 9, 56%). In the last evaluation, 9 cases had eye involvement. In two cases, eye examination was normal in the acute phase, while ocular involvement was present in the chronic period. In 4 (50%) patients, there was height and/or weight percentile loss. Three patients' SCARED scores and 2 patients' CDI scores were high. According to the CDLQI survey, SJS, TEN, or SJS/TEN overlap syndrome had a small to moderate effect on the QOL in the 43% (n = 6) of the patients. The ANA values of 3 patients (60%) were positive at the follow-up and negative at the first admission. Conclusion: SJS, TEN, and SJS/TEN overlap syndrome may cause sequelae even after a long time of the onset of the disease. Patients' QOL and psychological status can be affected negatively. Ocular symptoms may develop in the follow-up, even without involvement in the acute period. Patients with SJS, TEN, and SJS/TEN overlap syndrome should be followed up in the chronic period and approached multidisciplinary.
  • Publication
    Cystic fibrosis patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
    (European Respiratory Soc Journals Ltd, 2019-09-28) Çobanoğlu, Fatma Nazan; Ersöz, Deniz Doğru; Çakır, Erkan; Eyüboğlu, Tuğba Şişmanlar; Pekcan, Sevgi; Cinel, Güzin; Yalçın, Ebru; Kiper, Nural; Şen, Velat; Şen, Hadice Selimoglu; Ercan, Ömur; Keskin, Özlem; Eltan, Sevgi Bilgic; Al Shadfan, Lina Muhammed; Yazan, Hakan; Altintas, Derya Ufuk; Sasihuseyinoglu, Senay; Sapan, Nihat; Çekiç, Şükrü; Cokugras, Haluk; Atabek, Ayse Ayzit; Gursoy, Tugba Ramasli; Aslan, Ayse Tana; Bingol, Aysen; Basaran, Abdurrahman Erdem; Özdemir, Ali; Kose, Mehmet; Hangul, Melih; Emiralioglu, Nagehan; Tugcu, Gokcen; Yuksel, Hasan; Yilmaz, Özge; Orhan, Fazil; Aydin, Zeynep Gokce Gayretli; Topal, Erdem; Tamay, Zeynep; Süleyman, Ayşe; Can, Demet; Bal, Cem Murat; Caltepe, Gönül; Özçelik, Ugur; SAPAN, NİHAT; ÇEKİÇ, ŞÜKRÜ; Tıp Fakültesi; Çocuk İmmünoloji ve Alerji Hastalıkları Ana Bilim Dalı; 0000-0002-9574-1842 ; FUI-8766-2022; L-1933-2017
  • Publication
    Cftr mutations unidentified in cftr2 database and their phenotypic characteristics: Data from cystic fibrosis registry of Turkey
    (European Respiratory Soc Journals Ltd, 2020-09-07) Cinel, Güzin; Dogru, Deniz; Çakir, Erkan; Eyüboğlu, Tuğba Şişmanlar; Çobanoğlu, Nazan; Pekcan, Sevgi; Yalçın, Ebru; Kiper, Nural; Sen, Velat; Sen, Hadice Selimoğlu; Ercan, Ömür; Keskin, Özlem; Eltan, Sevgi Bilgiç; Al Shadfan, Lina Muhammed; Yazan, Hakan; Altıntaş, Derya Ufuk; Sasihüseyinoğlu, Şenay; Cokugras, Haluk; Atabek, Ayşe Ayzıt; Gürsoy, Tuğba Ramaşlı; Aslan, Ayşe Tana; Bingol, Aysen; Başaran, Abdurrahman Erdem; Özdemir, Ali; Köse, Mehmet; Hangül, Melih; Emiralioğlu, Nagehan; Tuğcu, Gökçen; Yüksel, Hasan; Yılmaz, Özge; Orhan, Fazıl; Aydın, Zeynep Gokçe Gayretli; Topal, Erdem; Tamay, Zeynep; Can, Demet; Bal, Cem Murat; Çaltepe, Gönül; Özçelik, Uğur; Sapan, Nihat; SAPAN, NİHAT; Çekiç, Sükrü; ÇEKİÇ, ŞÜKRÜ; Tıp Fakültesi; 0000-0002-9574-1842; L-1933-2017; FUI-8766-2022
  • Publication
    Evaluation of school age asthmatic cases with childhood asthma control test
    (Galenos Yayincilik, 2017-12-01) ÇEKİÇ, ŞÜKRÜ; SAPAN, NİHAT; CANITEZ, YAKUP; Demirbaş, Başak Ceylan; Tıp Fakültesi; Çocuk sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0002-9574-1842; L-1933-2017
    Introduction: Asthma is the most common chronic disease in children. It is known that seasonal changes affect the number of asthma attacks and the condition of the disease under control as well. We evaluated children aged 6-11 years of age who had been diagnosed with asthma using the childhood asthma control test (C-ACT) to determine the factors affecting the control of asthma.Methods: One hundred and three follow-up cases diagnosed with asthma between the ages of 6-11 were included. All cases were asked to fill in the C-ACT and the asthmatic questionnaire that we had prepared to evaluate the patients.Results: It was determined that the 47.5% of the cases (n=49) were under control according to the results of the C-ACT. The number of annual attacks in the group under control (median=2/year, minimum=0/year, maximum=10/year) was significantly less than for the uncontrolled cases (median=3.5/year, minimum=0/year, maximum=10/year) (p=0.005). We determined that 14.3% (n=7) of the families of the group under control and 38.9% (n=21) of the families of the uncontrolled cases had a history of eczema (p=0.005). The hospital admission rates of the group under control were found to be 30.6% (n=15) in September, 32.7% (n=16) in October, 30.6% (n=15) in November, and 6.10% (n=3) in December, and the rates for the uncontrolled cases were 5.6% (n=3) in September, 25.9% (n=14) in October, 33.3% (n=18) in November, and 35.2% (n=19) in December. We detected that the uncontrolled cases were admitted more frequently than the ones under control in December (p=0.001).Discussion and Conclusion: C-ACT is a practical application that helps physicians with the follow-up of patients. We have determined in our study that a significant percentage of the asthmatics are uncontrolled cases. We estimated that the increase of complaints in December in patients with asthma may be related to regional climatic changes as well as environmental conditions.
  • Publication
    Clinical findings of patients with cystic fibrosis according to newborn screening results
    (Wiley, 2022-01-01) Gürsoy, Tuğba Ramaslı; Aslan, Ayşe Tana; Asfuroğlu, Pelin; Eyuboğlu, Tuğba Sişmanlar; Çakır, Erkan; Cobanoğlu, Nazan; Pekcan, Sevgi; Cinel, Güzin; Doğru, Deniz; Özçelik, Uğur; Yalçın, Ebru; Sen, Velat; Ercan, Ömür; Kılınç, Ayse Ayzıt; Yazan, Hakan; Altıntaş, Derya Ufuk; Öztürk, Gökçen Kartal; Bingol, Aysen; Sapan, Nihat; Çelebioğlu, Ebru; Tugcu, Gökçen Dilşa; Özdemir, Ali; Harmancı, Koray; Köse, Mehmet; Emiralioğlu, Nagehan; Tamay, Zeynep; Yüksel, Hasan; Özcan, Gizem; Topal, Erdem; Can, Demet; Ekren, Pervin Korkmaz; Caltepe, Gönül; Kılıç, Mehmet; Özdoğan, Şebnem; SAPAN, NİHAT; Tıp Fakültesi; Çocuk Alerji ve İmmünoloji Ana Bilim Dalı; FUI-8766-2022
    Background Cystic fibrosis (CF) is a lethal recessive genetic disease caused by loss of function associated with mutations in the CF trans-membrane conductance regulator. It is highly prevalent (approximately 1 in 3,500) in Caucasians. The aim of this study was to compare demographic and clinical features, diagnostic tests, treatments, and complications of patients with CF whose newborn screening (NBS) with twice-repeated immune reactive trypsinogen testing was positive, normal, and not performed. Methods In this study, 359 of all 1,488 CF patients recorded in the CF Registry of Turkey in 2018, who had been born through the process of NBS, were evaluated. Demographic and clinical features were compared in patients diagnosed with positive NBS (Group 1), normal (Group 2), or without NBS (Group 3). Results In Group 1, there were 299 patients, in Group 2, there were 40 patients, and in Group 3, there were 20 patients. Among all patients, the median age at diagnosis was 0.17 years. The median age at diagnosis was higher in Groups 2 and 3 than in Group 1 (P = 0.001). Fecal elastase results were higher in Group 2 (P = 0.033). The weight z-score was lower and chronic Staphylococcus aureus infection was more common in Group 3 (P = 0.017, P = 0.004, respectively). Conclusions Frequency of growth retardation and chronic S. aureus infection can be reduced with an early diagnosis using NBS. In the presence of clinical suspicion in patients with normal NBS, further analyses such as genetic testing should be performed, especially to prevent missing patients with severe mutations.
  • Publication
    The success of the cystic fibrosis registry of Turkey for improvement of patient care
    (Wiley, 2022-02-11) Asfuroğlu, Pelin; Eyüboğlu, Tuğba Şişmanlar; Aslan, Ayşe Tana; Gürsoy, Tuğba Ramasli; Emiralioğlu, Nagehan; Yalçın, Ebru; Kiper, Nural; Sen, Velat; Sen, Hadice Selimoğlu; Altıntaş, Derya Ufuk; Özcan, Dilek; Kılınç, Ayşe Ayzit; Çokuğraş, Haluk; Başkan, Azer Kılıç; Yazan, Hakan; Erenberk, Ufuk; Doğan, Güzide; Ünal, Gökçen; Yılmaz, Aslı Imran; Keskin, Özlem; Arık, Elif; Küçükosmanoğlu, Ercan; Irmak, İlim; Damadoğlu, Ebru; Öztürk, Gökçen Kartal; Gülen, Figen; Başaran, Abdurrahman Erdem; Bingöl, Aysen; Çekiç, Sukru; Sapan, Nihat; Kılıç, Gonca; Harmancı, Koray; Köse, Mehmet; Özdemir, Ali; Tuğcu, Gökçen Dilsa; Polat, Sanem Eryılmaz; Hangül, Melih; Özcan, Gizem; Aydın, Zeynep Gökçe Gayretli; Yüksel, Hasan; Topal, Erdem; Özdoğan, Şebnem; Caltepe, Gönül; Süleyman, Ayşe; Can, Demet; Ekren, Pervin Korkmaz; Bal, Cem Murat; Kılıç, Mehmet; Cinel, Güzin; Çobanoğlu, Nazan; Pekcan, Sevgi; Çakir, Erkan; Özçelik, Uğur; Doğru, Deniz; ÇEKİÇ, ŞÜKRÜ; SAPAN, NİHAT; 0000-0001-7284-4999; 0000-0002-5360-8517; 0000-0002-7064-7585; 0000-0002-1405-8401; 0000-0002-2879-8910; 0000-0002-0086-3936; 0000-0002-7600-7909; 0000-0003-4291-7282; 0000-0003-2689-7904; 0000-0002-1824-2038; 0000-0001-5230-1575; 0000-0002-0793-9710; 0000-0002-0886-3332; 0000-0002-9574-1842; 0000-0002-3003-918X; 0000-0002-9804-1200; 0000-0003-2309-7952; 0000-0001-9063-4063; 0000-0002-1041-1124; 0000-0001-8525-6352; 0000-0002-1258-9348; 0000-0002-6209-196X; 0000-0002-3686-2927; 0000-0002-8059-902X; 0000-0003-1587-5216; 0000-0001-9931-9473; I-9089-2013; AAK-5467-2020; AER-7546-2022; ABG-5531-2021; AHD-5520-2022; L-1933-2017; ABG-5544-2021; JDC-4251-2023; HHN-5588-2022; A-1474-2013; AFX-2111-2022; AAM-9743-2021; AAK-5476-2020; AFN-3515-2022; AAF-8149-2020; AAA-7773-2020
    Background Cystic fibrosis (CF) registries play an essential role in improving disease outcomes of people with CF. This study aimed to evaluate the association of newly established CF registry system in Turkey on follow-up, clinical, growth, treatment, and complications of people with this disease. Methods Age at diagnosis, current age, sex, z-scores of weight, height and body mass index (BMI), neonatal screening results, pulmonary function tests, history of meconium ileus, medications, presence of microorganisms, and follow-up were evaluated and compared to data of people with CF represented in both 2017 and 2019 registry data. Results There were 1170 people with CF in 2017 and 1637 in 2019 CF registry. Eight hundred and fourteen people were registered in both 2017 and 2019 of whom z-scores of heights and BMI were significantly higher in 2019 (p = 0.002, p =0.039, respectively). Inhaled hypertonic saline, bronchodilator, and azithromycin usages were significantly higher in 2019 (p =0.001, p = 0.001, p = 0.003, respectively). The percent predicted of forced expiratory volume in 1 sec and forced vital capacity were similar in 2017 and 2019 (88% and 89.5%, p = 0.248 and 84.5% and 87%, p =0.332, respectively). Liver diseases and osteoporosis were significantly higher, and pseudo-Bartter syndrome (PBS) was significantly lower in 2019 (p = 0.011, p = 0.001, p = 0.001, respectively). Conclusions The z-scores of height and BMI were higher, the use of medications that protect and improve lung functions was higher and incidence of PBS was lower in 2019. It was predicted that registry system increased the care of people with CF regarding their follow-up. The widespread use of national CF registry system across the country may be beneficial for the follow-up of people with CF.